Addition of Abemaciclib to Fulvestrant Improves OS in HR+, HER2- Advanced Breast Cancer
The combined use of a CDK4/6 inhibitor with endocrine therapy yielded a 9.4-month median OS benefit among patients.
A new study confirms that a CDK4/6 blocker plus endocrine therapy is better than chemotherapy in young women with HR+, HER2- metastatic disease.Medscape Medical News
In a new study, patients with HR+/HER2- early stage breast cancer completed 2 years of adjuvant palbociclib with a similar toxicity profile as that observed in the metastatic setting.Annals of Oncology
Condition: Cancer Metastatic Interventions: Drug: Paclitaxel injection; Drug: Capecitabine tablets; Drug: Letrozole 2.5mg; Drug: Anastrozole 1mg; Drug: Fulvestrant Prefilled Syringe; Drug: Abemaciclib Sponsor: UNICANCER Not yet recruiting
Conclusions: Despite encouraging pre-clinical evidence, there is a lack of clinical data to inform CNS-specific response rates to CDK4/6 inhibitors among patients with metastatic breast cancer. Given that the treatment of patients with breast cancer brain metastases represents an area of unmet medical need, enrollment of patients with CNS metastases in ongoing clinical trials should be encouraged; innovative trials that examine response of CNS metastases to CDK4/6 inhibitors are also of interest. PMID: 31695840 [PubMed]
CONCLUSION: The DRP showed a potential in predicting fulvestrant treatment but was not significant in the overall analysis. Use of older biopsies, long-term endocrine treatment and multiple therapies between biopsy used for analysis and fulvestrant treatment, probably affect the predictive accuracy. PMID: 31654283 [PubMed - as supplied by publisher]
CONCLUSIONS: LPBC was marginally associated with higher pCR rate than non-LPBC in LT treated HER2+ BC patients. Quantitative assessment of the immune infiltrate by m-IF is feasible and may help correlate individual immune cell subpopulations and immune cell profiles with treatment response. PMID: 31653641 [PubMed - as supplied by publisher]
CONCLUSION: HRQoL was maintained on abemaciclib plus fulvestrant. Alongside superior PFS and manageable safety profile, results support treatment with abemaciclib plus fulvestrant in a population of patients with endocrine-resistant HR+, HER2-negative ABC. IMPLICATIONS FOR PRACTICE: In MONARCH 2, abemaciclib plus fulvestrant demonstrated superior efficacy and a manageable safety profile for patients with in hormone receptor-positive (HR+), HER2-negative (-) advanced breast cancer (ABC). Impact on health-related quality of life (HRQoL) is important to consider, given the palliative nature of ABC treatment. In this stud...
This article summarizes FDA decision-making and data supporting the approval of palbociclib for the treatment of male patients with HR-positive, HER2-negative advanced or metastatic breast cancer. PMID: 31649043 [PubMed - as supplied by publisher]
Abstract PURPOSE: To test the validity of OncoMasTR Molecular Score (OMm), OMclin1 and OncoMasTR Risk Score (OMclin2) prognostic scores for prediction of distant recurrence (DR) in ER-positive/HER2-negative breast cancer treated with 5 years' endocrine therapy only and compare their performance with the Oncotype DX Recurrence Score (RS). EXPERIMENTAL DESIGN: OMm incorporates three Master Transcription Regulator genes. OMclin1 combines OMm, tumor size, grade, nodal status; OMclin2 incorporates OMm, tumor size, nodal status. OMclin1 and OMclin2 were evaluated for 646 postmenopausal patients with ER-positive/HER...
Publication date: Available online 16 October 2019Source: European Journal of RadiologyAuthor(s): Bas H.M. van der Velden, Tycho Bismeijer, Sander Canisius, Claudette E. Loo, Esther H. Lips, Jelle Wesseling, Max A. Viergever, Lodewyk F.A. Wessels, Kenneth G.A. GilhuijsAbstractPurposeTo retrospectively explore the relation between parenchymal enhancement of the healthy contralateral breast on dynamic contrast-enhanced magnetic resonance imaging (MRI) and genomic tests for estrogen receptor (ER)-pathway activity in patients with ER-positive/HER2-negative cancer.MethodsA subset of 227 consecutively included patients with unil...